دانشکده داروسازی-Faculty of Pharmacy- كلية الصيدلة

: 13 مرداد 1398; بازدید: 3629; امتیاز:

( 0 Rating )

فعالیتهای تحقیقاتی دکتر علی بدیعی

امتیاز کاربران

Curriculum Vitae

Name: Ali

Surname: Badiee

Date of birth: 20. 09. 1975

Marital status: Married

E-mail: Badieeaاین آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید ; این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

P.O.Box: 91775-1365

Phone: +98-51-31801339

Fax: +98-51-38823251

Education:

1- Visiting Scholar: Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA (2014-2015)

2- Ph.D. in Pharmaceutics: School of Pharmacy, Mashhad University of Medical Science, Iran (2001-2006)

3- Research fellowship: School of Pharmacy/ Mater Medical Research Institute, University of Queensland, Australia. (Mar 2005-Nov 2005)

4- Pharm. D: School of Pharmacy, Mashhad University of Medical Science, Iran (1993 -1999)

Academic and Professional Positions Held:

1- Associate Professor: School of Pharmacy, Mashhad University of Medical Sciences, Mashhad-Iran (04/2013- present)

2- Assistant Professor: School of Pharmacy, Mashhad University of Medical Sciences, Mashhad-Iran (10/2008- 04/2013)

3- Researcher: Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran-Iran (1/2008- 10/2008)

4- Lecturer: School of Pharmacy, Zabol University of Medical Sciences, Zabol-Iran (2007-2008)

Technical Skills:

1- Commonly used immunological techniques for antigen processing and presentation (Flow cytometry, Fluorescence Microscopy, ELISpots, ELISA, Extra- or Intra-cellular cytokine Assay, Western blotting, IHC staining)

2- Analytical Instrument experiences (Size exclusion Chromatography, TLC, IR, UV-vis, Particle size Analyzer, Spectrofluorometry, Electrophoresis)

3- Preparation techniques for lipid-based particulate drug/vaccine delivery systems such as Liposomes, Immunoliposomes, Virosomes, ISCOMs, and LPD (Lipid Film method with Extrusion, Detergent removal, DRV, Ethanol Injection)

4- Care and Handling of Laboratory mice and rabbit

5- General cell culture techniques and parasite burden in animal tissue

6- Biostatistical methods for data analysis

Teaching Experiences:

1- Tumor Targeted Drug Delivery Systems, Vaccine Delivery systems, New Drug Approval Process & Clinical Trial Design, DNA Vaccines, Nanoparticles’ biodistribution, and Quality Control of Vaccines.

2- Pharmacy practice and Basic pharmacology.

Training Courses and Workshops:

1- Introduction to ICH/CTD guidance, 2012

2- Introduction to Standard Operating Procedures (SOP) for pharmaceutical compounds, 2012.

3- Introduction to intellectual property and patent search, 2011.

4- Introduction to research and research methods, 2010.

5- Scientific articles writing and publishing methods, 2010.

6- Overview of vaccine products and their quality controls, 2010.

7-Introduction to Whole animal body imaging, 2010.

8- Introduction to particle size analysis (PSA), 2009.

9- Introduction to atomic force microscopy (AFM), 2009.

10- Microsoft Word, Power Point, Excel, Outlook, SPSS, InStat, and GraphPad Prism, 2009.

11- Good Clinical Practice, 2009.

12- Biosafety practices and vaccine production, 2009.

13- Introduction to medical digital library resources, 2008.

14- Basic pharmacokinetic-pharmacodynamics in drug development, 2003.

Review for Journals:

1- International Journal of Biological Macromolecules

2- Oncotarget journal

3- Journal of Nanotechnology: Nanomedicine & Nanobiotechnology

4- Vaccine journal

5- Iranian Journal of Pharmaceutical Research

6- Iranian Journal of Basic Medical Sciences

Membership:

1-Editorial board, Nanomedicine Journal, since 2012.

2- Director of MUMS Pharmaceutical Technology Incubator, 2011-2014.

3- Member of Nanotechnology Research Center of MUMS, since 2009.

4- Member of Iranian Medical Council since 2000.

Honors & Awards:

1- Best PhD dissertation, 11^th Iranian seminar of pharmaceutical scientists, Iran, 2008 (Offered by Iranian association of pharmaceutical scientists).

2- Ranked second in modern technology, 13^th Razi Research Festival on Medical Sciences, Iran, 2007.

3- A six-month scholarship awarded by Iranian Ministry of Health and Medical Education in UQ, Australia, 2005.

Research Interests:

1- Liposomal vaccine/drug delivery systems

2-Drug, Protein, or Peptide formulations

3- Lipid based nanoparticles as immunoadjuvants

Current Research:

1-Chemoimmunotherapy against Leishmaniasis or cancer with lipid based nanoparticles

Ph. D.& Pharm. D. Dissertations Completed under Mentorship:

Ph. D.

1- Ahmad Mehravaran, Formulation, physicochemical characterization and evaluation of induced immune response with ISCOM nanoparticles containing Leishmania antigens in murine model (2013-2015).

2- Seyedeh Alia Moosavian, Formulation and characterization of nanoliposomal doxorubicin targeted with anti- Her-2/neu aptamer and evaluation of their anti tumor effects in vitro and in vivo in mice bearing Her-2/neu expressing breast cancer (2012-2015).

3- Mercedeh Mansourian, Preparation and characterization of positively charged fusogenic liposomes containing Her2 peptides and MPL or CpG-ODN adjuvant as a vaccine against breast cancer and evaluation of generated immune response in mice model (2012-2015).

4- Mahnaz Nourbakhsh, Evaluation of effects of nanolipoparticles containing MDR1 siRNA on drug resistance in doxorubicin resistant breast cancer cells (MCF-7/Adr) (2011-2014).

5- Omid Chavoshian, Formulation and physicochemical characterization of virosomes containing Leishmania antigens and evaluation of induced immune response in murine model (2010- 2013 ).

6- Amir Hossein Sahebkar, Preparation and evaluation of nanoliposomes conjugated with apolipoprotein B-100 antibodies as a therapeutic option for serum LDL reduction (2010-2013).

7-Mohammad Reza Amin, Formulation and characterization of nanoliposomal doxorubicin prepared with DChemsPC or DShemsPC and targeted with RGD peptides, and in vitro/in vivo evaluation of their anti tumor effects in mice bearing C26 colon carcinoma tumor (2009- 2013 ).

Pharm. D.

1- Fatemeh Fazaeli, Optimization of preparation method for nanoliposomal soluble Leishmania antigens and characterization of their physicochemical properties (2012-2015).

2- Sara Shokohh Saremi, In vitro uptake evaluation of different nanoliposome formulations containing soluble leishmania antigens by bone marrow-derived dendritic cells of C57BL/6 mice (2013-2014).

3-Maryam Shahriari, In vitro uptake evaluation of different nanoliposome formulations containing soluble leishmania antigens by bone marrow-derived dendritic cells of BALB/c mice (2013-2014).

4-Alireza komeilinezhad, Preparation and characterization of ISCOMATRIX nanoparticles (2012-2013).

5-Zahra Mohammaddamini, in vivo evaluation of immunoadjuvant potential of iscomatrix when co-administered with PR8 influenza virus (2012-2013).

6- Arezoo Sobhani, Formulation and characterization of nanoliposomal doxorubicin targeted with sphingomyelin and evaluation of their citotoxicity effects, in vitro on C26 colon carcinoma tumor (2012-2013).

7- Laleh Naghibi, Formulation and characterization of a conjugated Her2 peptide (P435+P5) nanoliposomes containing MPL adjuvant as a vaccine against breast cancer and evaluation of their immune responses and anti tumor effects in murine model (2012-2014)

8- Niloofar Farzad, Formulation and characterization of a conjugated Her2 peptide (P435) nanoliposomes containing MPL adjuvant as a vaccine against breast cancer and evaluation of their immune responses and anti tumor effects in murine model (2012-2014)

9- Razieh Ghoorchian, Preparation, physicochemical properties assay and in vitro evaluation of targeting efficiency of nanoliposomes containing Leishmania antigens to human dendritic cells (2012-2013).

10- Hamed Eshaghian, In vitro evaluation of targeting efficiency of nanoimmunoliposomes containing Leishmania antigen to human dendritic cells (2012-2013).

11- Mahsa Bagheri, Formulation and characterization of nanoliposomal doxorubicin targeted with Tat peptide and evaluation of their antitumor effects in vitro and in vivo on C-26 colon carcinoma cell line (2012-2013).

12- Ghazal Alipour Talesh, Preparation of nanoliposomes containing Her2 peptide and Poly(I:C) adjuvant as vaccine against breast cancer and evaluation of their immunological response and anti tummor effects (2013-2014).

13- Amir Hossein Sabbaghi, Preparation and characterization of chitosan and trimethylchitosan nanoparticles loaded with influenza virus, with or without alginate coat, for nasal immunization to mouse (2012-2013).

14- Seyede Shima Mirkazemi, Preparation and study of physicochemical properties of nanoliposomes containing soluble leishmania antigens and MPL adjuvant (2010-2011).

15- Iman jaafari, Preparation, characterization, and evaluation of induced immune response by nanoliposomes containing whole Leishmania lysate antigens in a mouse model (2010-2011).

16- Hesamoddine Hosseinjani, Evaluation of lesion development and type of immune response generated in mice inoculated with L. major mixed with cationic nanoliposomes containing CpG ODN (2009-2010).

17- Hadi Naseri, Evaluation of using PEG polymer on physicochemical and generated immune response properties of cationic liposomes containing soluble Leishmania antigens (2010-2011).

18- Mahdieh Morakkabi, Preparation, characterization, and evaluation of induced immune response by nanoliposomes containing whole Leishmania lysate antigen with MPL in a mouse model (2011-2012).

19- Zahra Akbari Nooghabi, Preparation, characterization, and evaluation of induced immune response by positively charged nanoliposomes containing soluble Leishmania antigens in mouse model of Leishmania (2011-2012).

20- Fatemeh Fakhraee pishbaghan, Preparation and characterization of LPD-nanoparticles containing rgp63 and rLmaC1N and evaluation of immune response stimulation against leishmaniasis in murine model (2010-2012).

21- Nazanin Biari, Preparation, characterization, and evaluation of induced immune response by sphingomyelin nanoliposomes containing whole Leishmania lysate antigen with MPL in a mouse model (2010-2012).

22- Faeze Eskandari, Evaluation of protection rate and immune response against nanoliposomes containing Leishmania antigen in murine model (2010-2011).

23- Zohreh Taziki, Formulation and characterization of nanoliposomal doxorubicin targeted with TAT peptides and evaluation of their antitumor effects, in vitro in C26 colon carcinoma (2011-2012).

24- Ensieh Golali, Preparation and physicochemical characterization of nanoliposomes containing Leishmania antigens and PO CpG ODN and the immune response in murine model (2010-2011).

25- Morteza Akbari, Formulation, characterization and in vivo evaluation of nanoliposomes containing curcumin for the topical treatment of leishmaniasis cutaneous lesion in murine model (2009-2011).

26- Maryam parooie, Preparation, study of physicochemical properties of nanoimmunoliposomes containing Leishmania antigen and evaluation of protection rate and immune response against antigen in murine model (2009-2011).

27- Bent-alhoda Nabavi, Formulation and characterization of nanoliposomal doxorubicin targeted with TAT peptides and in vitro evaluation of their anti tumor effects in mice bearing C26 colon carcinoma tumor (2009-2011).

28- Vahid Heravi shargh, Preparation, study of physicochemical properties of nanoliposomes coencapsulated with Leishmania antigen and CpG oligodeoxynucleotides containing phosphodiester backbone (PO-CpG ODN) and evaluation of protection rate and immune response against antigen in murine model (2009-2010).

29- Seyede Hoda Alavizadeh, Evaluation of lesion development and type of immune response generated in mice inoculated with L. major mixed with LPD nanoparticles containing CpG ODN (2008-2010).

Patents:

1- Inventors: A. Sahebkar, Ali Badiee, M. R. Jaafari, 2015, METHOD AND COMPOSITION FOR TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES, United States Patent Application 20150147383-

Peer Reviewed Journal Publications:

1-S. A. Moosavian, K. Abnous, A. Badiee, M. R. Jaafari, 2016. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model, Colloids and Surfaces B: Biointerfaces, 139,228-236.

2- S. H. Alavizadeh, J. Akhtari, A. Badiee, S. Golmohammadzadeh, M. R. Jaafari, 2015. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models, Expert opinion on drug delivery, 16, 1-12.

3- A. Mehravaran, M. R. Jaafari, S. A. Jalali, A. Khamesipour, M. Tafaghodi, M. Hojatizade, A. Badiee, 2015. The role of surface charge of ISCOMATRIX nanoparticles on the type of immune response generated against Leishmaniasis in BALB/c mice, Nanomedicine J., 4, 249-260.

4- L. Arabi, A. Badiee, F. Mosaffa, M. R. Jaafari, 2015. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin, J Control. Release, 220, 275-286.

5- M. Amin, M. Mansourian, G. A. Koning, A. Badiee, M. R. Jaafari, T. L.M. ten Hagen, 2015. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region, J Control. Release, 220, 308-315.

6- A. R. Nikpoor, J. Tavakkol-Afshari, Z. Gholizadeh, K. Sadri, M. H. Babaei, J. Chamani, A. Badiee, S. A. Jalali, M. R. Jaafari, 2015. Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model, Int. J. Pharm., 495 (1), 162-170.

7- M. Teymouri, H. Farzaneh, A. Badiee, S. Golmohammadzadeh, K. Sadri, M. R. Jaafari, 2015. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma, Eur. J. Pharm. Sci., doi:10.1016/j.ejps.2015.08.011

8- S. A. Moosavian, M. R. Jaafari, S. M. Taghdisi, F. Mosaffa, A. Badiee, K. Abnous, 2015. Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX, Iran J Basic Med Sci., 18(6), 576-586.

9- S. Shariat, A. Badiee, S. A. Jalali, M. Mansourian, S. A. Mortazavi, M. R. Jaafari, 2015. Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects, Iran J Basic Med Sci., 18(5), 506-513.

10- A. Sahebkar, A. Badiee, M. Hatamipour, M. Ghayour-Mobarhan, M. R. Jaafari, 2015. Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia, Colloids Surf B Biointerfaces., 129, 71-78.

11- M. Nourbakhsh, M. R. Jaafari, H. Lage, K. Abnous, F. Mosaffa, A. Badiee, J. Behravan, 2015. Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer, Iran J Basic Med Sci., 18(4), 385-392.

12- M. Nourbakhsh, J. Behravan, H. Lage, K. Abnous, F. Mosaffa, A. Badiee, M. R. Jaafari, 2015. Nanolipoparticles-mediated MDR1 siRNA delivery: preparation, characterization and cellular uptake, Nanomedicine journal, 2(1), 39-45.

13- F. Eskandari, G. A. Talesh, M. Parooie, M. R. Jaafari, A. Khamesipour, Z. Saberi, A. Abbasi, A. Badiee, 2014. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of Leishmaniasis, Exp. Parasitol., 146, 78-86

14- S. Shariat, A. Badiee, S. A. Jalali, M. Mansourian, M. Yazdani, S. A. Mortazavi, M. R. Jaafari, 2014. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer, Cancer Lett., 355, 54-60.

15- A. Sahebkar, A. Badiee, M. Ghayour-Mobarhan, S. R. Goldouzian, M. R. Jaafari, 2014. A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes, Colloids Surf B Biointerfaces., 122, 645-652.

16- M. Mansourian, A. Badiee, S. A. Jalali, S. Shariat, M. Yazdani, M. Amin, M. R. Jaafari, 2014. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN, Immunol Lett., 162 (1), 87-93.

17- S. H., Alavizadeh, A. Badiee, S. Golmohammadzadeh, M. R. Jaafari, 2014. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma, Int J Pharm., 473, 326-333.

18- S. Shariat, A. Badiee, M. R. Jaafari, S. A. Mortazavi, 2014. Optimization of a method to prepare liposomes containing HER2/neu- derived peptide as a vaccine delivery system for breast cancer, Iran J Pharm Res., 13, 15-25.

19- M. Amin, A. Badiee, M. R. Jaafari, 2013. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas, Int J Pharm., 458, 324-333.

20- H. Firouzmand, A. Badiee, A. Khamesipour, V. H. Shargh, H. Alavizadeh, A. Abbasi, M. R. Jaafari, 2013. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA), Acta Tropica, 128, 528-535.

21- O. Chavoshian, N. Biari, A. Badiee, A. Khamesipour, A. Abbasi, Z. Saberi, S. A. Jalali, M. R. Jaafari, 2013. Sphingomyelin liposomes containing soluble Leishmania major antigens induced strong Th2 immune response in BALB/c mice, Iran J Basic Med Sci., 16, 965-972.

22- H. Hoseinjani, M. R. Jaafari, A. Khamesipour, A. Abbasi, Z. Saberi, A. Badiee, 2013. Evaluation of infection course in mice induced by L. major in presence of positively charged liposomes containing CpG ODN, Nanomedicine Journal, 1, 30-40.

23- A. Badiee, V. H. Shargh, A. Khamesipour, M. R. Jaafari, 2013, Micro/nanoparticle adjuvants for antileishmanial vaccines: Present and future trends, Vaccine, 31, 735-749, Review article.

24- A. Badiee, M. R. Jaafari, A. Khamesipour, A. Samiei, D. Soroush, V. H. Shargh, M. Tavassoti Kheiri, F. Barkhordari, W. R. Mc Master, F. Mahboudi, 2012. The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen, Experimental Parasitology, 132, 403–409.

25- E. Golali, M. R. Jaafari, A. Khamesipour, A. Abbasi, Z. Saberi, A. Badiee, 2012. Comparison of in vivo adjuvanticity of liposomal PO CpG ODN with liposomal PS CpG ODN: leishmaniasis as a model, Iranian Journal of Basic Medical Sciences, 15, 1032-1045.

26- H. Alavizadeha, A. Badiee, A. Khamesipour, S. A. Jalali, H. Firouzmand, A. Abbasi, M. R. Jaafari, 2012. Evaluation of lesion development and type of immune response generated in BALB/c mice inoculated with L. major mixed with LPD nanoparticles containing CpG ODN, Experimental Parasitology, 132, 313-319.

27- V. H. Shargh, M. R. Jaafari, A. Khamesipour, I. Jaafari, S. A. Jalali, A. Abbasi, A. Badiee, 2012. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis, Vaccine, 30, 3957-3964.

28- V. H. Shargh, M. R. Jaafari, A. Khamesipour, S. A. Jalali, H. Firouzmand, A. Abbasi, A. Badiee, 2012. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis, Parasitology Research, 111, 105-114.

29- H. Hejazi, M. Tasbihi, M. R. Jaafari, A. Badiee, N. Pestechian, A. Javadi, A. Khamesipour, 2010. The role of liposomal CpG ODN on the course of L. major infection in BALB/c mice, Iranian J Parasitol, 5(1), 47-54.

30- A. Badiee, M. R. Jaafari, A. Khamesipour, A. Samiei, D. Soroush, M. T. Kheiri, F. Barkhordari, W. R. McMaster, F. Mahboudi, 2009. The role of liposome charge on immune response generated in BALB/c mice immunized with rgp63, Experimental Parasitology, 121, 362-369.

31- A. Badiee, M. R. Jaafari, A. Khamesipour, 2009. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition, Colloids and Surfaces B: Biointerfaces, 74(1), 37-44.

32- A. Badiee, M. R. Jaafari, A. Samiei, D. Soroush, A. Khamesipour, 2008. Co-encapsulation of CpG ODN with rLmSTI1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice, Clinical and Vaccine Immunology, 15, 668-674.

33- A. Badiee, N. M. Davies, K. McDonald, K. Radford, H. Michiue, D. N. J. Hart, M. Kato, 2007. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205, Vaccine, 25, 4757–4766.

34- M. R. Jaafari, A. Badiee, A. Samiei, D. Soroush; M. T. Kheiri, F. Barkhordari, A. Khamesipour, W. R. McMaster, F. Mahboudi, 2007. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome, Vaccine, 25, 6107–6117.

35- A. Badiee, M. R. Jaafari, A. Khamesipour, 2007. Leishmania major: Immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes, Experimental Parasitology, 115, 127-134.

36- Y. Sohrabi, M. R. Jaafari, A. Badiee, S. H. Hejazi, S. E. Eskandari, A. M. Mohammadi, A. Khamesipour, 2007. Evaluation of immune response against autoclaved Leishmania major incorporated into positively charged liposomes in BALB/c mice, Iranian Journal of Dermatology, 10, 37-53.

37- A. Badiee, M. R. Jaafari, A. Samiei, D. Soroush, A. Khamesipour, 2006. Immune response evaluation against leishmaniasis using liposomes containing rLmSTI1 in murine model, Iranian Journal of Basic Medical Sciences, 8, 215-225.

38- H. A. Garekani, F. Sadeghi, A. Badiee, S. A. Mostafa, A. R. Rajabi-Siahboomi, 2001. Crystal habit modifications of ibuprofen and their physico-mechanical characteristics, Drug Development and Industrial Pharmacy, 27, 803-809.

39- H. A. Garekani, F. Sadeghi, A. Badiee, 1999, Investigation of the physico-mechanical properties of modified crystals of ibuprofen, Iranian Journal of Basic Medical Sciences, 2, 8-17.

Conference Presentations:

Oral presentations

1- A. Badiee, Lipid-based nanoparticles as vaccine adjuvant and delivery systems: present and future trends, 11^th International Congress of Immunology & Allergy (Iran, 2012, Keynote speaker).

2- A. Badiee, M. R. Jaafari, A. Khamesipour, Liposomes as vaccine delivery systems for soluble Leishmania antigens (SLA): where are we today?, 5^th Iranian Controlled release Conference (Iran, 2011).

3- A. Badiee, M. Parooei, M. R. Jaafari A. Khamesipour., Preparation and physicochemical characterization of nanoimmunoliposomes containing SLA as a vaccine against Leishmaniasis, 1st Nanodrugs Congress (Iran, 2011).

4- A. H. Alavizadeh, M. R. Jaafari, A. Badiee, A. Khamesipour, A. Jalali, A. Abbasi, Evaluation of lesion development and type of immune response generated in mice inoculated with L. major mixed with LPD Nanoparticles containing CpG ODN, 3^rd Conference on Nanostructures (Iran, 2010).

5- A. Badiee, M. R. Jaafari, A. Khamesipour, Formulation, characterization and evaluation of immune response of liposomes containing leishmania antigen and CpG ODN against leishmaniasis in murine model, 4^th Iranian Controlled Release Conference (Iran, 2009).

6- A. Badiee, M. Kato, D. N. J. Hart, N. M. Davies, Preparation and characterization of anti-hDEC-205 immunoliposome nanoparticles for targeting to human dendritic cells, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S27.

7- M.R. Jaafari, A. Badiee, A. Khamesipour, A. Samiei, D. Soroush, A. Abbasi, M. Tavassoti Kheiri, F. Barkhordari, F. Mahboudi, Immunization of BALB/c Mice against Leishmaniasisusing LPD nanoparticles containing rgp63 and rLmaCIN prepared with CpG oligodeoxynucleotides, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S41.

8- A. Badiee, M. Kato, D. N. J. Hart, N. M. Davies, Enhanced delivery of anti-hDEC-205 immunoliposomes to human dendritic cells: A strategy for DC-based cancer immunotherapy, 19^th Asia Pacific Cancer Conference, (Iran, 2007).

9- M. R. Jaafari, A. Badiee, A. Samiei, D. Soroush, A. Khamesipour, M. Amani, F. Mahboudi, Vaccination of BALB/c mice against cutaneous leishmaniasis using liposomes containing rgp63 and CpG ODNs, Third World Congress on Leishmaniosis, (Italy, 2005).

Posters and published Abstracts

1- A. Sahebkar, S.R. Goldouzian, A. Badiee, M. R. Jaafari. A novel nanoliposomal approach for the treatment of severe hyperlipidemia. Iranian Controlled Release Congress, 2011.

2- A. Badiee, M. R. Jaafari, A. Khamesipour, A. Abbasi, Z. Saberi, Preparation and characterization of nanoliposomes containing soluble Leishmania antigens and MPL adjuvant, 13th Iranian Pharmaceutical Sciences Congress (Iran, 2012), Res. Pharm. Sci., 7 (5), S238.

3- F. Mosaffa, M. R. Jafaari, L. Arabi, A. Badiee, Isolation and identification of putative cancer stem cells in C26 murine colon carcinoma cell line, 13th Iranian Pharmaceutical Sciences Congress (Iran, 2012), Res. Pharm. Sci., 7 (5), S462.

4- M. Bagheri, A. Badiee, M. R. Jaafari, 13th Iranian Pharmaceutical Sciences Congress (Iran, 2012), Res. Pharm. Sci., 7 (5), S214.

5- A. Badiee, M. R. Jaafari, M. R. Amin, Antitumor efficacy of RGD-targeted liposomes containing doxorubicin in mice bearing C-26 colon carcinoma, 13th Iranian Pharmaceutical Sciences Congress (Iran, 2012), Res. Pharm. Sci., 7 (5), S1003.

6- M. Parooei, M. R. Jaafari A. Khamesipour. A. Badiee, Preparation and physicochemical characterization of immunoliposome nanoparticles as a vaccine delivery system: Leishmaniasis as a model, 12^th Iranian Congress of Biochemistry & 4^th International Congress of Biochemistry & molecular Biology (Iran, 2011), Clinical Biochemistry 44 (13), S216.

7- A. M. Eslahtalab, A. Badiee, Dendritic cells-based cancer vaccines: The role of lipid-based nanoparticles, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S59.

8- H. Alavizadeh, A. Badiee, M. R. Jaafari, Lipid-protamine-DNA (LPD) nanoparticles as a vaccine delivery system for cancer immunotherapy, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S130.

9- M. R. Amin, A. Badiee, M. R. Jaafari, Nanoparticulate systems in cancer detection and therapy, The Specialized Congress And International Exhibition Of Nanomedicine, Nanobiotechnology, Nanobiosensors And Nanomaterials, (Iran, 2009), Iran J Basic Med Sci., 12(2), S155.

10- M. R. Jaafari, A. Badiee, A. Samiei, D. Soroush; M. T. Kheiri, F. Barkhordari, A. Khamesipour, F. Mahboudi, The role of liposome charge on immune response generated in BALB/c mice immunized with rgp63, 11^th Liposome Research Days Conference, (Japan, 2008).

11- M. R. Jaafari, A. Badiee, A. Samiei, D. Soroush, A. Khamesipour, Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition, 3^rd ILS Annual Meeting: Liposome Advances, (UK, 2007).

12- A. Badiee, M. R. Jaafari, A. Khamesipour, Immunization of BALB/c mice against cutaneous Leishmaniasis by Leishmania major strees inducible protein 1 encapsulated in liposomes,10^th Iranian Pharmaceutical Ssciences Conference, (Iran, 2006).

13- A. Badiee, M. R. Jaafari, A. Samiei, D. Soroush, J. Webb, A. Khamesipour, Immunization of BALB/c mice against cutaneous leishmaniasis using liposomes containing rLmSTI1 and CpG ODNs, Third World Congress on Leishmaniosis, (Italy, 2005).

14- H. A. Garekani, F. Sadeghi, A. Badiee, A. R. Rajabi-Siahboomi, Crystal habit modifications of ibuprofen and their physico-mechanical characteristics., 19th Pharmaceutical Technology Conference, (Italy, 2000).

15- S. Shojaiee, Y. Sohrabi, A. Badiee, Effect of Gentamycine on stimulation of immune system in rabbit. Proceeding of the 4th congress of Iranian pharmacy students, (Iran, 1997).

Referees:

1- Professor Mahmoud Reza Jaafari:

Ph.D. Thesis supervisor,

School of Pharmacy, Mashhad University of Medical Sciences, Iran